ANL vs AURA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AURA Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aura Biosciences, Inc. Common Stock (AURA) driven by superior Growth & Margin, Options & Structure while ANL counters with relative strength in Momentum & Technical. Fundamentally, ANL trades at N/M Forward P/E with -123.5% operating margin (+178.1% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANL | AURA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $677.5M | $728.6M | Larger Scale | AURA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +178.1% | +0.0% | Higher Growth | ANL |
| Operating Margin (TTM) Profitability | -123.5% | 0.0% | Higher Margin | AURA |
| Net Profit Margin Profitability | -124.8% | 0.0% | Higher Margin | AURA |
| Return on Equity (ROE) Capital Efficiency | -20.2% | -61.7% | Higher ROE | ANL |
| 52-Week Range Position Momentum | 56% ($1โ$17) | 52% ($5โ$10) | Stronger Trend | ANL |
| Beta / 30D Volatility Risk Regime | 2.61ฮฒ ยท 79% Vol | 0.92ฮฒ ยท 75% Vol | Lower Realized Risk | AURA |
| Unified Institutional Score Composite Signal | 48.3 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | ANL |